X
Details:
The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space by including Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for FRα positive platinum-resistant ovarian cancer (PROC).
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $10,100.0 million Upfront Cash: $10,100.0 million
Deal Type: Acquisition February 12, 2024
Iran Expo
Not Confirmed
Contact SupplierDetails:
The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space by including Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
Lead Product(s): Mirvetuximab Soravtansine-gynx
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $10,100.0 million Upfront Cash: $10,100.0 million
Deal Type: Acquisition November 30, 2023
Iran Expo
Not Confirmed
Contact Supplier
Details:
Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Under the agreement, ImmunoGen has retained production rights and will supply product for development and commercial use in Japan and Takeda will receive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings and obligations.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $34.0 million
Deal Type: Collaboration August 28, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
The collaboration will combine ImmunoGen's proprietary linker-payload technology with ImmunoBiochem's antibodies directed against specific targets to develop next-generation antibody-drug conjugates.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: ImmunoBiochem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 24, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
ImmunoGen intends to use the proceeds to fund its operations, including global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, pipeline research and development activities, business development, and capital expenditures.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $373.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 09, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
ImmunoGen intends to use the net proceeds to fund its operations, including, but not limited to, global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, clinical trial activities, pipeline research and development activities.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $325.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platinum-resistant ovarian cancer.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Under the terms of the agreement, the loan facility will be available to Company upon achievement of positive top-line data from its confirmatory MIRASOL trial and a net sales threshold for ELAHERE™ (mirvetuximab soravtansine-gynx).
Lead Product(s): Mirvetuximab Soravtansine-gynx
Therapeutic Area: Oncology Product Name: Elahere
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pharmakon Advisors
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 06, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Vertex will have the rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing. CTX001 (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $352.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement March 01, 2023
Iran Expo
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
